The transaction involved the sale of 925,000 shares, also at $12.06 a share.
According to its website, Derma Sciences is a tissue regeneration company "at the forefront of research and innovation for the management of acute and chronic wounds, and burns".
Comvita, which has a market capitalisation of $478.9 million, has been a star performer on the NZX.
The stock tripled in price in the year, hitting a record high $12.40 last month. They traded today at $12.00 a share.
This week, the company said its annual net profit jumped to $17.2 million from $10.2 million the year earlier, based on increased Australian sales, and up from November forecast for a profit of $15m-$17m.